Skip to main content
SpringerLink
Log in

Anti-PSMA Antibody-Drug Conjugates and Immunotoxins

  • Chapter
  • First Online:
Book cover Antibody-Drug Conjugates and Immunotoxins

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 2531 Accesses

Abstract

The prostate-specific membrane antigen (PSMA) represents a valuable antigen for the generation of antibody–drug conjugates (ADCs), since it is present on the cell surface at all tumor stages, overexpressed in advanced and metastatic disease, not shed into circulation, and internalized after antibody binding. Moreover, due to expression in the neovasculature of many solid tumors, but not in the normal vascular endothelium, PSMA represents an ideal target for ADCs designed to destroy the tumor vasculature.

In recent years, various types of anti-PSMA ADCs were generated by linking radionuclides, toxins of different origin, or viruses to anti-PSMA monoclonal antibodies or antibody fragments. In vitro and in vivo testing in preclinical and clinical trials showed a proof of concept for these constructs. Therefore, anti-PSMA ADCs can be regarded as promising candidates for an alternative treatment of advanced prostate cancer. The present chapter gives an overview of these approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249

    Article  PubMed  Google Scholar 

  2. Meulenbeld HJ, Hamberg P, de Wit R (2009) Chemotherapy in patients with castration-resistant prostate cancer. Eur J Cancer 45(Suppl 1):161–171

    Article  PubMed  Google Scholar 

  3. O’Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C, Vonder Haar RA, Fair WR, Heston WD (1998) Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1443(1–2):113–127

    PubMed  Google Scholar 

  4. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK (2003) A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 14(12):4835–4845

    Article  PubMed  CAS  Google Scholar 

  5. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25(6):1375–1384

    Article  PubMed  CAS  Google Scholar 

  6. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ (2005) Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 102(17):5981–5986

    Article  PubMed  CAS  Google Scholar 

  7. Carter RE, Feldman AR, Coyle JT (1996) Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93(2):749–753

    Article  PubMed  CAS  Google Scholar 

  8. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2(9):1445–1451

    PubMed  CAS  Google Scholar 

  9. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58(18):4055–4060

    PubMed  CAS  Google Scholar 

  10. Liu J, Kopeckova P, Buhler P, Wolf P, Pan H, Bauer H, Elsasser-Beile U (2009) Kopecek J. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells, Mol Pharm

    Google Scholar 

  11. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82(11):2256–2261

    Article  PubMed  CAS  Google Scholar 

  12. Wolf P, Freudenberg N, Buhler P, Alt K, Schultze-Seemann W, Wetterauer U, Elsasser-Beile U (2010) Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 70(5):562–569

    PubMed  CAS  Google Scholar 

  13. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3(1):81–85

    PubMed  CAS  Google Scholar 

  14. Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7(5B):927–935

    PubMed  CAS  Google Scholar 

  15. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC (1990) Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50(19):6423–6429

    PubMed  CAS  Google Scholar 

  16. Wright GLJ, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28

    Article  PubMed  Google Scholar 

  17. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48(2):326–334

    Article  PubMed  Google Scholar 

  18. Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52(4):637–640

    Article  PubMed  CAS  Google Scholar 

  19. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9(17):6357–6362

    PubMed  CAS  Google Scholar 

  20. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57(17):3629–3634

    PubMed  CAS  Google Scholar 

  21. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59(13):3192–3198

    PubMed  CAS  Google Scholar 

  22. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30(4):628–636

    Article  PubMed  Google Scholar 

  23. Chang SS, Reuter VE, Heston WD, Gaudin PB (2001) Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 57(6):1179–1183

    Article  PubMed  CAS  Google Scholar 

  24. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF, Gardiner RA (2002) Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 100(2):228–237

    Article  PubMed  CAS  Google Scholar 

  25. Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D (2009) The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One 4(2):e4608

    Article  PubMed  Google Scholar 

  26. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54(7):1807–1811

    PubMed  CAS  Google Scholar 

  27. Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62(5):552–558

    Article  PubMed  CAS  Google Scholar 

  28. Heston WD (1997) Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 49(Suppl 3A):104–112

    Article  PubMed  CAS  Google Scholar 

  29. O’Keefe DS, Bacich DJ, Heston WD (2004) Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 58(2):200–210

    Article  PubMed  Google Scholar 

  30. Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J (2007) Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144(4):1361–1372

    Article  PubMed  CAS  Google Scholar 

  31. Chang SS, Reuter VE, Heston WD, Gaudin PB (2001) Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 57(4):801–805

    Article  PubMed  CAS  Google Scholar 

  32. Baccala A, Sercia L, Li J, Heston W, Zhou M (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70(2):385–390

    Article  PubMed  Google Scholar 

  33. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26(14):5310–5324

    Article  PubMed  CAS  Google Scholar 

  34. Troyer J, Feng Q, Beckett M, Wright GJ (1995) Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate specific membrane antigen. Urological. Oncology 1:29–37

    CAS  Google Scholar 

  35. Brown LG, Wegner SK, Wang H, Buhler KR, Arfman EW, Lange PH, Vessella RL (1998) A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts. Prostate Cancer Prostatic Dis 1(4):208–215

    Article  PubMed  CAS  Google Scholar 

  36. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL (2001) Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int J Cancer 92(6):871–876

    Article  PubMed  CAS  Google Scholar 

  37. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH (1998) Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 160(6 Pt 2):2396–2401

    PubMed  CAS  Google Scholar 

  38. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL (1998) Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58(21):4787–4789

    PubMed  CAS  Google Scholar 

  39. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370

    Article  PubMed  Google Scholar 

  40. Moffett S, Melancon D, DeCrescenzo G, St-Pierre C, Deschenes F, Saragovi HU, Gold P, Cuello AC (2007) Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use. Hybridoma (Larchmt) 26(6):363–372

    Article  CAS  Google Scholar 

  41. Regino CA, Wong KJ, Milenic DE, Holmes EH, Garmestani K, Choyke PL, Brechbiel MW (2009) Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm 2(1):9–17

    Article  PubMed  CAS  Google Scholar 

  42. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC (2003) The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 100(22):12590–12595

    Article  PubMed  Google Scholar 

  43. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25(5):540–547

    Article  PubMed  CAS  Google Scholar 

  44. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT (1998) 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159(6):2041–2046

    Article  PubMed  CAS  Google Scholar 

  45. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, Weiner GJ, Bushnell D, Gulfo J (1994) Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152(5 Pt 1):1490–1495

    PubMed  CAS  Google Scholar 

  46. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B (1996) Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin Nucl Med 21(10):759–767

    Article  PubMed  CAS  Google Scholar 

  47. Haseman MK, Reed NL, Rosenthal SA (1996) Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 21(9):704–713

    Article  PubMed  CAS  Google Scholar 

  48. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH (1998) Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83(11):2259–2269

    Article  PubMed  CAS  Google Scholar 

  49. Rosenthal SA, Haseman MK, Polascik TJ (2001) Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 7(1):27–37

    PubMed  CAS  Google Scholar 

  50. Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (1999) A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm 14(2):99–111

    Article  PubMed  CAS  Google Scholar 

  51. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S (1996) Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 2(8):1289–1297

    PubMed  CAS  Google Scholar 

  52. Elsasser-Beile U, Reischl G, Wiehr S, Buhler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla HJ, Pichler BJ (2009) PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 50(4):606–611

    Article  PubMed  Google Scholar 

  53. Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Elsasser-Beile U, Buhler P (2010) High-resolution animal PET imaging of prostate cancer xenografts with three different (64)Cu-labeled antibodies against native cell-adherent PSMA. Prostate 70(13):1413–1421

    Article  PubMed  CAS  Google Scholar 

  54. Behe M, Alt K, Deininger F, Bühler P, Wetterauer U, Weber WA, Elsässer-Beile U, Wolf P (2011) In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo 25(1):55–59

    PubMed  CAS  Google Scholar 

  55. David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH (2006) Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clin Genitourin Cancer 4(4):249–256

    Article  PubMed  CAS  Google Scholar 

  56. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA (2000) An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 60(21):6095–6100

    PubMed  CAS  Google Scholar 

  57. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH (2004) Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 58(2):145–155

    Article  PubMed  CAS  Google Scholar 

  58. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22(13):2522–2531

    Article  PubMed  CAS  Google Scholar 

  59. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21):4591–4601

    Article  PubMed  CAS  Google Scholar 

  60. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH (2005) Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 46(5):850–858

    PubMed  CAS  Google Scholar 

  61. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M (2002) Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 53(1):9–23

    Article  PubMed  CAS  Google Scholar 

  62. Sandvig K, Torgersen ML, Engedal N, Skotland T, Iversen TG (2010) Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. FEBS Lett 584(12):2626–2634

    Article  PubMed  CAS  Google Scholar 

  63. Knowles PP, Thorpe PE (1987) Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. Anal Biochem 160(2):440–443

    Article  PubMed  CAS  Google Scholar 

  64. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR (1988) Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 48(22):6396–6403

    PubMed  CAS  Google Scholar 

  65. Foxwell BM, Donovan TA, Thorpe PE, Wilson G (1985) The removal of carbohydrates from ricin with endoglycosidases H, F and D and alpha-mannosidase. Biochim Biophys Acta 840(2):193–203

    Article  PubMed  CAS  Google Scholar 

  66. Kimura Y, Hase S, Kobayashi Y, Kyogoku Y, Ikenaka T, Funatsu G (1988) Structures of sugar chains of ricin D. J Biochem 103(6):944–949

    PubMed  CAS  Google Scholar 

  67. Huang X, Bennett M, Thorpe PE (2004) Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 61(1):1–11

    Article  PubMed  CAS  Google Scholar 

  68. Stirpe F, Barbieri L, Battelli MG, Soria M, Lappi DA (1992) Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology (NY) 10(4):405–412

    Article  CAS  Google Scholar 

  69. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH (2010) Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 70(12):1286–1294

    PubMed  CAS  Google Scholar 

  70. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC (2006) Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 12(8):2591–2596

    Article  PubMed  CAS  Google Scholar 

  71. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778–784

    Article  PubMed  CAS  Google Scholar 

  72. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ (2004) A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64(21):7995–8001

    Article  PubMed  CAS  Google Scholar 

  73. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, McKenzie SJ, Goldmacher VS (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 52(1):127–131

    PubMed  CAS  Google Scholar 

  74. Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LM, Frei E 3rd (1978) A therapeutic trial of maytansine. Cancer Clin Trials 1(2):113–117

    PubMed  CAS  Google Scholar 

  75. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13):2147–2154

    Article  PubMed  CAS  Google Scholar 

  76. Russell PJ, Hewish D, Carter T, Sterling-Levis K, Ow K, Hattarki M, Doughty L, Guthrie R, Shapira D, Molloy PL, Werkmeister JA, Kortt AA (2004) Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother 53(5):411–421

    Article  PubMed  CAS  Google Scholar 

  77. Dunn RD, Weston KM, Longhurst TJ, Lilley GG, Rivett DE, Hudson PJ, Raison RL (1996) Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin. Immunotechnology 2(3):229–240

    Article  PubMed  CAS  Google Scholar 

  78. Wolf P, Gierschner D, Buhler P, Wetterauer U, Elsasser-Beile U (2006) A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother 55(11):1367–1373

    Article  PubMed  CAS  Google Scholar 

  79. Wolf P, Alt K, Wetterauer D, Buhler P, Gierschner D, Katzenwadel A, Wetterauer U, Elsasser-Beile U (2010) Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J Immunother 33(3):262–271

    Article  PubMed  CAS  Google Scholar 

  80. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763

    Article  PubMed  CAS  Google Scholar 

  81. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF 3rd, Bookman MA, Fand I, Houston LL, Weiner LM (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53(17):4026–4034

    PubMed  CAS  Google Scholar 

  82. Allured VS, Collier RJ, Carroll SF, McKay DB (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 83(5):1320–1324

    Article  PubMed  CAS  Google Scholar 

  83. Wedekind JE, Trame CB, Dorywalska M, Koehl P, Raschke TM, McKee M, FitzGerald D, Collier RJ, McKay DB (2001) Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J Mol Biol 314(4):823–837

    Article  PubMed  CAS  Google Scholar 

  84. Wolf P, Alt K, Buhler P, Katzenwadel A, Wetterauer U, Tacke M, Elsasser-Beile U (2008) Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate 68(2):129–138

    Article  PubMed  CAS  Google Scholar 

  85. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I (1999) Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 163(11):6072–6077

    PubMed  CAS  Google Scholar 

  86. Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, Lee B, Pastan I (2001) Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 61(13):5070–5077

    PubMed  CAS  Google Scholar 

  87. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, Hassan R, Pastan I (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177(12):8822–8834

    PubMed  CAS  Google Scholar 

  88. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW (2009) Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 69(10):1128–1141

    Article  PubMed  CAS  Google Scholar 

  89. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69(1):82–91

    Article  PubMed  CAS  Google Scholar 

  90. Munguia A, Ota T, Miest T, Russell SJ (2008) Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 15(10):797–806

    Article  PubMed  CAS  Google Scholar 

  91. Power AT, Bell JC (2008) Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 15(10):772–779

    Article  PubMed  CAS  Google Scholar 

  92. O’Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10(8):1349–1358

    Article  PubMed  Google Scholar 

  93. Carlisle RC, Benjamin R, Briggs SS, Sumner-Jones S, McIntosh J, Gill D, Hyde S, Nathwani A, Subr V, Ulbrich K, Seymour LW, Fisher KD (2008) Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med 10(4):400–411

    Article  PubMed  CAS  Google Scholar 

  94. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA (2006) Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103(34):12873–12878

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Experimental Urology, University Medical Center Freiburg, Breisacher Strasse 117, D-79106, Freiburg, Germany

    Philipp Wolf

Authors
  1. Philipp Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Wolf .

Editor information

Editors and Affiliations

  1. DNA Way 1, South San Francisco, 94080, California, USA

    Gail Lewis Phillips

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wolf, P. (2013). Anti-PSMA Antibody-Drug Conjugates and Immunotoxins. In: Phillips, G. (eds) Antibody-Drug Conjugates and Immunotoxins. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5456-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5456-4_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5455-7

  • Online ISBN: 978-1-4614-5456-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation